tiprankstipranks
Trending News
More News >
Indraprastha Medical Corporation Limited (IN:INDRAMEDCO)
:INDRAMEDCO
India Market
Advertisement

Indraprastha Medical Corporation Limited (INDRAMEDCO) AI Stock Analysis

Compare
0 Followers

Top Page

IN:INDRAMEDCO

Indraprastha Medical Corporation Limited

(INDRAMEDCO)

Select Model
Select Model
Select Model
Neutral 68 (OpenAI - 4o)
Rating:68Neutral
Price Target:
₹626.00
▲(9.10% Upside)
Indraprastha Medical Corporation Limited's overall stock score is driven by strong financial performance and bullish technical indicators. However, the high P/E ratio and overbought RSI suggest caution, as the stock may be overvalued with potential for a near-term correction.

Indraprastha Medical Corporation Limited (INDRAMEDCO) vs. iShares MSCI India ETF (INDA)

Indraprastha Medical Corporation Limited Business Overview & Revenue Model

Company DescriptionIndraprastha Medical Corporation Limited provides hospital services in India. It offers services primarily in the areas of anesthesiology, pediatric, elder care, genomic medicine, health check, sugar, bariatric and metabolic surgery, bone marrow transplant, cancer, cardiac and cardiology, dermatology, dietetics and clinical nutrition, emergency care, endovascular surgery, endocrinology/diabetes care, ENT, fetal medicine, gastroenterology and hepatology, laparoscopic surgery, gynecology and obstetrics, hyperbaric oxygen therapy, IVF, internal medicine, laboratory services, neonatology, nephrology, neurosciences, nuclear medicine, ophthalmology, orthopedic, pediatric urology and pediatric surgery, physiotherapy and rehabilitation, psychiatry and clinical psychology, radiology/radio diagnosis, respiratory sleep medicine and critical care, rheumatology, robotic surgery, spine surgery, transfusion medicine, transplant, and urology and andrology. The company operates cosmetic and dental clinics. Indraprastha Medical Corporation Limited was incorporated in 1988 and is based in New Delhi, India.
How the Company Makes MoneyIndraprastha Medical Corporation Limited generates revenue primarily through the provision of healthcare services. The company's key revenue streams include patient fees for consultations, medical treatments, and surgical procedures. Additionally, it earns income from diagnostic services, outpatient services, and emergency care. The company may also engage in partnerships with insurance providers to facilitate patient access to its services, thereby broadening its customer base and ensuring a steady stream of revenue. Furthermore, ancillary services such as pharmacy sales and laboratory tests contribute to the company's overall earnings.

Indraprastha Medical Corporation Limited Financial Statement Overview

Summary
Indraprastha Medical Corporation Limited exhibits strong financial health with consistent revenue growth and profitability. The balance sheet reflects low leverage and solid equity, although attention to cash management is advised due to recent declines in cash reserves. The financial statements indicate a well-managed company with potential for continued growth, albeit with a need for vigilant cash flow management.
Income Statement
85
Very Positive
Indraprastha Medical Corporation Limited has demonstrated strong revenue growth over the years, increasing from 5,960 million INR in 2021 to 13,563 million INR in 2025. The gross profit margin has improved significantly, indicating strong operational efficiency, and the net profit margin has also shown consistent improvement, reaching 11.87% in 2025. The EBIT and EBITDA margins reflect healthy profitability, contributing to a robust income statement performance.
Balance Sheet
75
Positive
The company maintains a solid equity position with a debt-to-equity ratio consistently low, indicating low leverage risk. Return on equity has improved, reflecting efficient use of equity capital. The equity ratio is strong, showing financial stability; however, the decrease in cash and cash equivalents from 2024 to 2025 indicates potential liquidity considerations.
Cash Flow
70
Positive
The cash flow statements reveal stable operational cash flows, though there was a decline in free cash flow in 2025 compared to the previous year. The free cash flow to net income ratio is healthy, suggesting effective cash generation relative to profit. However, the decline in operating cash flow in 2025 needs monitoring to ensure continued liquidity.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue13.74B13.56B12.45B10.99B8.88B6.13B
Gross Profit3.69B3.50B3.13B6.25B4.79B3.47B
EBITDA2.69B2.44B2.07B1.61B1.17B409.48M
Net Income1.68B1.61B1.24B861.50M586.20M23.30M
Balance Sheet
Total Assets0.008.52B7.23B5.55B4.62B4.32B
Cash, Cash Equivalents and Short-Term Investments3.22B3.19B2.24B1.36B660.10M296.10M
Total Debt0.00327.60M339.50M24.80M53.10M78.18M
Total Liabilities-5.97B2.55B2.45B1.76B1.36B1.59B
Stockholders Equity5.97B5.97B4.78B3.79B3.25B2.73B
Cash Flow
Free Cash Flow0.001.20B1.31B998.90M418.10M69.35M
Operating Cash Flow0.001.57B2.00B1.44B712.90M278.98M
Investing Cash Flow0.00-1.11B-1.58B-1.08B-511.00M-201.62M
Financing Cash Flow0.00-458.80M-323.80M-260.40M-33.70M-31.47M

Indraprastha Medical Corporation Limited Technical Analysis

Technical Analysis Sentiment
Positive
Last Price573.80
Price Trends
50DMA
463.65
Positive
100DMA
453.14
Positive
200DMA
437.41
Positive
Market Momentum
MACD
7.38
Negative
RSI
78.66
Negative
STOCH
87.31
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:INDRAMEDCO, the sentiment is Positive. The current price of 573.8 is above the 20-day moving average (MA) of 473.66, above the 50-day MA of 463.65, and above the 200-day MA of 437.41, indicating a bullish trend. The MACD of 7.38 indicates Negative momentum. The RSI at 78.66 is Negative, neither overbought nor oversold. The STOCH value of 87.31 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:INDRAMEDCO.

Indraprastha Medical Corporation Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
69
Neutral
₹238.83B29.540.67%4.35%32.89%
68
Neutral
₹43.84B26.140.78%6.80%21.31%
68
Neutral
₹107.23B70.100.71%12.86%10.42%
67
Neutral
₹169.60B47.630.66%14.49%13.70%
66
Neutral
₹463.45B48.771.97%6.65%48.47%
60
Neutral
₹463.38B108.340.14%6.80%-75.66%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IN:INDRAMEDCO
Indraprastha Medical Corporation Limited
573.80
160.36
38.79%
IN:BIOCON
Biocon Limited
348.05
5.56
1.62%
IN:CONCORDBIO
Concord Biotech Ltd.
1,628.30
-260.72
-13.80%
IN:GLAXO
GlaxoSmithKline Pharmaceuticals Limited
2,735.75
73.55
2.76%
IN:METROPOLIS
Metropolis Healthcare Ltd.
2,111.75
-164.00
-7.21%
IN:PFIZER
PFIZER LIMITED
5,223.55
-239.72
-4.39%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 08, 2025